-
ALSO READ
Cadila hits 52-week low on 14 observations from USFDA for Moraiya plant
Regulatory issues bridle pharma returns, USFDA scrutiny a major hurdle
Zydus Pharma gets USFDA nod to market attention-deficit hyperactivity drug
Zydus Cadila's US arm Nesher Pharma gets 11 observations from USFDA
What's bugging Indian, Chinese medicine companies making crucial heart drug
-
Drug firm Cadila Healthcare on Thursday said it has received approval from the USFDA for Haloperidol Decanoate injection used in treatment of schizophrenia.
The product will be manufactured at Liva Pharma's manufacturing facility at Vadodara, Cadila Healthcare said in a BSE filing.
Haloperidol is used in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette syndrome.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU